



Review

Self-Antigens Targeted by Regulatory T Cells in Type 1 Diabetes

Angela M. Mitchell and Aaron W. Michels *

Barbara Davis Center for Diabetes, University of Colorado, Aurora, CO 80045, USA;
angela.mitchell@cuanschutz.edu

* Correspondence: aaron.michels@cuanschutz.edu; Tel.: +1-303-724-1923

Abstract: While progress has been made toward understanding mechanisms that lead to the development of autoimmunity, there is less knowledge regarding protective mechanisms from developing such diseases. For example, in type 1 diabetes (T1D), the immune-mediated form of diabetes, the role of pathogenic T cells in the destruction of pancreatic islets is well characterized, but immune-mediated mechanisms that contribute to T1D protection have not been fully elucidated. One potential protective mechanism includes the suppression of immune responses by regulatory CD4 T cells (Tregs) that recognize self-peptides from islets presented by human leukocyte antigen (HLA) class II molecules. In this review, we summarize what is known about the antigenic self-peptides recognized by Tregs in the context of T1D.

Keywords: regulatory T cells; type 1 diabetes; islet autoimmunity; antigen-specific therapy



Citation: Mitchell, A.M.; Michels, A.W. Self-Antigens Targeted by Regulatory T Cells in Type 1 Diabetes. *Int. J. Mol. Sci.* **2022**, *23*, 3155. <https://doi.org/10.3390/ijms23063155>

Academic Editor: Dumitru Constantin-Teodosiu

Received: 4 February 2022

Accepted: 12 March 2022

Published: 15 March 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Type 1 diabetes (T1D) is an autoimmune disease that typically presents in childhood and early adulthood that results in the destruction of insulin-producing pancreatic beta cells by T cells [1–4]. The primary pathological presentation of T1D is inflammation of the pancreatic islets, termed insulinitis, and it is due to the infiltration of immune cells, including CD4 and CD8 T cells along with B cells [5–10]. Therefore, there is a direct link between pathogenic T cells targeting insulin-producing pancreatic beta cells; however, regulatory T cells (Tregs) play an important role in protection from autoimmunity, including T1D. During T1D development, there is likely an imbalance between pathogenic T cells targeting pancreatic islets and Tregs that function to protect against targeting these cells.

The incidence of T1D continues to increase globally across racial and ethnic groups [11]. However, the measurement of T1D-associated antibodies in the peripheral blood allows for the prediction of disease progression through stages, as islet autoantibodies precede the development of clinical diabetes, in general, by a number of years [12–14]. Furthermore, a recent study has shown that short-term immunotherapy with an anti-CD3 monoclonal antibody can delay the onset of clinical disease [15], which is marked by hyperglycemia and the need for exogenous insulin treatment. Despite these clinically meaningful successes, there is a strong need in the field to specifically induce tolerance to islet antigens prior to and at disease onset. In this review, we aim to describe what is known regarding the specific antigens that are targeted by regulatory T cells in type 1 diabetes, and we will summarize ongoing antigen-specific therapeutic strategies for preventing disease onset.

2. T Cell Receptor–Peptide–MHC Interactions

T cells possess T cell receptors (TCRs) that recognize peptides bound to major histocompatibility complex (MHC) molecules on the surface of antigen-presenting cells (APCs) such as B cells, dendritic cells, and macrophages. TCRs consist of an alpha chain and beta chain that are generated via the recombination of noncontiguous gene segments for each

chain. Both chains of the TCR include a variable (V), joining (J), and constant region, while the beta chain also contains a diversity (D) region. Therefore, the process by which TCRs are rearranged into fully functional receptors is known as V(D)J recombination. In this manner, each T cell generates a unique receptor for the recognition of a closely related set of peptides presented in the context of the MHC molecule. The interaction between TCR/peptide/MHC leads to activation of the T cells, and two major classes of T cells are involved in an adaptive immune response. Both classes recognize peptide/MHC, and cluster of differentiation 4 (CD4) T cells release cytokines to activate other immune cells and also interact with and activate B cells, while CD8 T cells act to directly kill target cells. CD4 cells can generally be subdivided into T helper type 1 (Th1) and type 2 (Th2) cells, which are distinguished by their functions and cytokine production. Th1 cells are considered proinflammatory due to their production of the cytokines interleukin-2 (IL-2) and interferon gamma (IFN- γ). Th1 cells function to direct immune responses against intracellular viral and bacterial pathogens. Th2 cells are considered more anti-inflammatory and produce the cytokines IL-4, IL-5, and IL-13 to generate immune responses directed against extracellular pathogens. Regulatory T cells (Tregs) are another subtype of CD4 T cells that suppress immune responses via multiple mechanisms, including the secretion of anti-inflammatory cytokines (e.g., IL-10 and transforming growth factor beta (TGF- β)), the expression of regulatory cell surface receptors (e.g., cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)), and the direct killing of APCs via perforin and granzyme B.

T cells are directly involved in the immunopathogenesis of T1D, and the link between autoimmunity and particular MHC alleles has been well established. In fact, numerous studies have demonstrated that MHC is the major genetic determinant for T1D [16–24]. Conversely, the presence of diabetes-resistant MHC alleles in transgenic mouse models can both induce the deletion of autoreactive T cells and also promote the development of Tregs [19–21]. Therefore, the MHC genotype may determine the balance between proinflammatory and anti-inflammatory responses to a given self-antigen. In humans, MHC proteins are encoded by the human leukocyte antigen (HLA) genes, and variants of these genes can confer significant disease risk or protection from autoimmune diseases, including T1D [25]. For example, individuals with the HLA-DQ8 (DQB1*03:02) allele have an odds ratio for T1D development of 11, while those with HLA-DQ6 (DQB1*06:02) are protected from T1D with an odds ratio of only 0.03 [26–28]. T1D research has primarily been focused on identifying peptides that activate T cells via presentation by diabetes risk MHC class II molecules [29]. However, little is known about the mechanisms by which protective MHC molecules provide dominant protection from T1D development.

3. Immunologic Tolerance by Regulatory T Cells

Two types of Tregs include thymus-derived natural Tregs (nTregs) and peripherally induced Tregs (iTregs). nTregs express the transcription factor forkhead box P3 (Foxp3) and suppress other T cell subsets during inflammation, whereas iTregs are conventional T cells that are induced to express Foxp3 and become regulatory in peripheral lymphoid tissues. A subtype of iTreg cells, known as type 1 regulatory (Tr1) cells, do not express high levels of Foxp3 but rather CD49b and lymphocyte-activation gene 3 (LAG-3) and are able to produce high levels of both IL-10 and TGF- β [30,31]. Thus, Tr1 cells are potent suppressors of other T cell subsets via cytokine-mediated mechanisms. However, Tr1 cells can also mediate suppression via granzyme-mediated killing in a cell contact-dependent fashion [32]. Distinct subtypes of Tr1 cells have now been identified in both humans and mice, and the subtypes differ primarily in their cytokine secretion profiles [33].

Tregs are not only important for the return to a homeostatic state after an immune response, but they are also critical for the prevention of autoimmunity. For example, Tregs induce tolerance in the periphery by suppressing autoreactive T cells that are specific for self-tissues. However, the precise molecular mechanisms by which Tregs suppress auto-antigen-specific T cells are unknown, and it is of interest to determine which antigens are being recognized by Tregs to prevent autoimmunity. It is appreciated that T1D patients

do not lack overall numbers of Tregs but likely have a functional defect in bulk Tregs, which contributes to disease development [34–37]. However, we will focus on studies that identified and evaluated islet antigen-specific Tregs in autoimmune T1D.

4. Antigen-Specific Tregs in Type 1 Diabetes

Although the deletion of most autoreactive T cells occurs in the thymus, self-reactive T cells do escape and are able to circulate in the periphery [38]. These escaped self-reactive T cells can be controlled by Tregs as one mechanism of peripheral tolerance. Determining the specificity of these Tregs may aid in understanding the mechanisms involved in the loss of tolerance to self-antigens that occurs during autoimmunity and identifying specific antigens and epitopes that may be utilized for antigen-specific immunotherapy to treat the underlying autoimmunity.

In T1D, Kwok et al. showed that islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP)-specific T cells from healthy individuals and those with T1D could produce both proinflammatory (i.e., IFN- γ) and anti-inflammatory (i.e., IL-10) cytokines, indicating that antigen-specific Th1 cells and Tregs are present in the peripheral blood [39]. The IGRP-specific T cells were detected using HLA-DR4 and -DR3 tetramers, and therefore, they were of high avidity for peptide/MHC. However, because both pro- and anti-inflammatory IGRP-specific T cells were present in healthy individuals in addition to T1D patients, the results indicate that the escape of high avidity self-reactive T cells is not sufficient to cause disease. Likely, there is an imbalance in the pathogenic CD4 T cells and protective Tregs, as measured by pro- and anti-inflammatory cytokine responses, to islet self-antigens that skews the response during T1D development with a threshold needing to be met for autoreactive T cells to target pancreatic islets.

Data in support of a cytokine imbalance toward self-antigens come from studies in our laboratory that measured cytokine responses to native and mutated insulin B chain peptides using a cytokine enzyme linked immunospot (ELISPOT) assay with peripheral blood immune cells from new-onset T1D patients as well as non-diabetic controls [40]. Importantly, the majority of individuals in both groups were carrying at least one diabetes-risk HLA allele (e.g., DQ8 or DQ2). The strongest proinflammatory T cell responses were found in response to a mutated insulin peptide—much more than the native peptide sequence. The amino acid substitution in the mutated insulin B chain peptide (B22R→E) allows the peptide to bind in an otherwise unfavorable register to T1D-risk HLA molecules (i.e., DQ8 and DQ2). In addition, anti-inflammatory responses were present in the vast majority of the non-diabetic subjects and several T1D patients. Both the IFN- γ and the IL-10 responses were greater in non-diabetic individuals who carried at least one non T1D-risk DQ allele. These results indicate that in non-diabetic individuals, the presence of a diabetes protective or neutral HLA-DQ molecule may lead to a regulatory T cell response to insulin, whereas in T1D individuals, this ability may be muted or absent. Other studies using cytokine ELISPOT assays with epitopes from beta cell specific self-antigens, proinsulin, and insulinoma-associated antigen 2 (IA-2) provide similar results with a proinflammatory response in disease and regulatory response in health [41,42].

Recently, we identified both pro- and anti-inflammatory cytokine T cell responses to hybrid insulin peptides (HIPs) from longitudinal peripheral blood samples of individuals genetically at risk for T1D who either developed islet autoantibodies or remained seronegative [43]. HIPs are neoantigens that form in the lysosomes of beta cells via a covalent bond between a fragment of C-peptide and another peptide from a beta cell protein [44]. In this manner, autoreactive T cells that are specific for HIPs may escape into the periphery because these neoantigens are not presented in the thymus during T cell education. In this study, individuals who became autoantibody positive or who progressed to clinical T1D (high blood sugars requiring exogenous insulin treatment) had a predominantly proinflammatory response to the HIPs, and these responses correlated to worsening measurements of blood glucose control. Separate studies have also found T cell responses to HIPs in newly diagnosed T1D patients [45–47].

As islet antigen-specific Tregs are present within healthy individuals, these cells have been cloned after culture with IA-2 (IA-2709–736) or proinsulin peptides (B:11–30, B:9–28) [48]. Interestingly, although the cells produced IL-10 in response to the islet antigen and were able to suppress the proliferation of T cells, the study found that direct cell-to-cell contact was required for the suppression to occur. The autoantigen-specific Tregs were further able to express cytotoxic molecules (i.e., granzyme A and granzyme B) and directly kill islet autoantigen-loaded antigen-presenting cells in a perforin/granzyme-dependent manner. These results indicate that antigen-specific Tregs are potent regulators of pathogenic T cells as well as antigen presenting cells in healthy individuals.

The age of T1D onset may also help direct T cell responses to beta cell proteins, as Ueno et al. measured CD4 T cell responses to glutamic acid decarboxylase (GAD), proinsulin, and IGRP in adult-onset versus childhood-onset T1D patients [49]. In adult patients, there was predominantly a Th1 response to IGRP, whereas those with childhood onset had a Th2 immune response with Tr1 regulatory cells. In fact, the frequency of Tr1 cells responding to IGRP in adult-onset patients was much lower than in childhood-onset patients and non-diabetic controls. These results indicate that distinct subsets of CD4 T cells may respond to IGRP differently and could influence the timing of disease onset.

Taken together, these studies indicate that during T1D disease development, there are anti-inflammatory responses to islet autoantigens; however, there is either a defect in that response or the proinflammatory immune response predominates. This concept is highlighted by data from a spontaneous animal model of autoimmune diabetes in which there are regulatory T cells within the inflamed pancreatic islets that are directed against an immunodominant peptide, insulin B:9–23, but insulinitis and diabetes still develop [50]. At the current time, it is unknown and under investigation whether islet antigen-specific Tregs are present in human insulinitis.

5. Structural Basis of a Treg T Cell Receptor Recognizing Peptide/MHC

To better understand the structural basis of a proinsulin-specific Treg, Rossjohn et al. solved the crystal structure of a Treg T cell receptor (TCR) binding to proinsulin/DR4 and compared this to the canonical TCR docking pattern for a proinsulin-specific effector T cell [51]. Proinsulin-specific Tregs were cloned and then induced to become iTregs via interaction with tolerogenic dendritic cells. Typically, the α chain of the TCR docks over the β chain of the MHC class II molecule, while the β chain of the TCR docks over the MHC α . However, this Treg crystal structure determined that the TCR α chain overlaid the MHC α chain, while the TCR β chain overlaid the β chain of the proinsulin/DR4 complex. Thus, a possible structural mechanism exists with reversed polarity docking of the TCR that may account for the difference in response when Tregs recognize a self-antigen versus effector T cells for the same peptide/MHC complex. Although the study identified a novel docking motif for proinsulin-specific Tregs in the context of DR4, it is unknown whether this unusual docking motif extends to other Treg cell specificities at this time.

In a separate study, two murine CD8 T cell receptors specific for a nucleoprotein epitope (NP₃₆₆) presented by the MHC class I molecule, H-2D^b, docked with a 180 degree position relative to other CD8 TCR-peptide-MHC class I complexes [52]. Although not a Treg TCR-peptide-MHC class II interaction, the authors found that the responses were defective in downstream signal transduction and proliferative capacity. Therefore, irregular docking of a TCR on a peptide-MHC complex may play an important role in how T cells respond to various peptides, including self-peptides. There is a need in the field to understand the structural interactions of Treg TCRs with self-peptide/MHC complexes (e.g., TCR affinity and X-ray crystallography) and compare these interactions to effector T cells binding similar peptide/MHC complexes.

6. Diabetes-Protective MHC Molecules Present Self-Antigens to Activate Tregs

A recent study observed that both GAD- and IGRP-specific Tregs were in higher frequencies in individuals with the T1D protective haplotype of HLA-DR15/DQ6 [53].

Tetramers consisting of either DQ6 or DR15 and several different GAD or IGRP epitopes were used to stain peripheral blood from non-diabetic individuals directly ex vivo. Both effector and regulatory antigen-specific T cells were observed in individuals with the protective haplotype. Importantly, the DR15-restricted GAD- and IGRP-specific Tregs were able to suppress the proliferation of GAD- and IGRP-specific effector T cells, including those activated by the T1D-risk DQ8 molecule. These findings provide a mechanism by which dominant protection is afforded by DQ6/DR15 when the DQ8 allele is also present. Of note, the Treg suppression did not require cell-to-cell contact, but the maximal response was achieved when it was permitted, which is in agreement with separate studies of islet-antigen specific Tregs [48]. These results indicate that a higher frequency of Tregs recognizing islet autoantigens in the context of T1D-resistant MHC molecules may be responsible for protection from T1D development. A similar phenomenon is likely present in Goodpasture's disease (autoimmune targeting of the basement membrane proteins in the lung and kidneys) in which an epitope of the $\alpha 3$ chain of type IV collagen ($\alpha 3_{135-145}$) is presented by both the risk-conferring DR15 molecule and the protective DR1 molecule, albeit in different binding registers. HLA-DR15 presentation of the epitope results in a T cell response that is predominantly proinflammatory, while DR1 results in CD4+ Foxp3+ Treg responses [54].

Taken together, these studies indicate that antigen-specific Tregs are present in both healthy and T1D individuals. Several different peptides from beta cell antigens have been identified as epitopes for Tregs in the peripheral blood and are summarized in Table 1. However, it is unknown which of the antigen-specific Tregs are important for protection from autoimmunity, whether autoimmunity is due to defects in these Tregs, and also at what disease stage the potentially defective antigen-specific Tregs might play a role (e.g., prior to seroconversion, after seroconversion, or at clinical disease onset). Future studies are warranted to address these questions in order to understand the role of Tregs in the stages of T1D disease pathogenesis. Furthermore, identifying and characterizing antigen-specific Tregs that mediate protection from T1D and other autoimmune diseases have important therapeutic implications.

Table 1. Select antigen-specific Treg studies in human type 1 diabetes.

Method	Autoantigen Target(s) [HLA(s)]	Primary Outcome	References
Tetramer staining	IGRP [DR3, DR4]	IL-10	[39]
Cytokine ELISPOT	Insulin B:9–23; mimotopes [DQ8]	IL-10	[40]
	HIPs [DQ8]	IL-10	[42,43]
	Proinsulin, IA-2 [DR4]	IL-10	[41]
Cloning, cytokine ELISA; flow cytometry	Proinsulin, IA-2 [DR3, DR4]	IL-10; granzyme A, B; Treg suppression	[48]
Cytokine beads; flow cytometry	GAD65, PPI, IGRP	IL-10; IP-10	[49]
Cloning; cytokine ELISA; flow cytometry; TCR-peptide-MHC crystallization	Proinsulin [DR4]	IL-10, granzyme B; TCR-peptide-MHC docking	[51]
Tetramer staining, cloning, flow cytometry	GAD, IGRP, PPI, ZnT8 [DR3, DR4, DR15, DQ6]	IL-10; Treg suppression	[53]

Treg: regulatory T cell; HLA: human leukocyte antigen; ELISpot: enzyme-linked immune absorbent spot; ELISA: enzyme-linked immunosorbent assay; IGRP: islet-specific glucose-6-phosphatase catalytic subunit-related protein; HIP: hybrid insulin peptide; IA-2: islet antigen-2; GAD65: glutamic acid decarboxylase 65-kilodalton isoform, PPI: preproinsulin; ZnT8: zinc transporter 8; IL: interleukin; TCR: T cell receptor; MHC: major histocompatibility complex.

7. Therapeutic Strategies to Enhance Tregs in Type 1 Diabetes

Therapies to increase Treg numbers have been tested clinically in T1D, and it has been established that Tregs can selectively expand in response to the administration of low-dose IL-2 [55,56]. Several early-phase clinical trials have been completed showing safety at low doses and as a single agent that increases CD4⁺ CD25⁺ Foxp3⁺ cells, and larger efficacy trials are underway in newly diagnosed children and adults [57–64]. Another approach to increasing Treg numbers has focused on expanding autologous Tregs *ex vivo* and reinfusing these cells back into the same T1D patient from which the cells were obtained [65,66]. The goal is to expand Tregs in an antigen-independent fashion (i.e., polyclonally) so as tip the balance in favor of an anti-inflammatory environment that may lead to protection of the remaining beta cells. A more recent phase I study combined the adoptive transfer of expanded autologous polyclonal Tregs with low-dose IL-2 [67]. With the addition of IL-2, the infused Tregs and endogenous Tregs increased in numbers for approximately 6–12 weeks after the last dose of IL-2. However, activated natural killer (NK) cells, mucosal-associated invariant T cells, and populations of CD8 T cells also increased from baseline. There was no preservation of endogenous insulin production in the participants as measured by C-peptide, which is secreted 1:1 with insulin from the beta cell. These results indicate the need to more specifically target IL-2 to avoid off-target effects. As such, engineered or mutated IL-2 using IL-2 cytokine-receptor orthogonal pairs to transmit IL-2 signals can expand Tregs but not NK or CD8 T cells in murine models [68], making this an attractive therapeutic approach once translated to human IL-2. Furthermore, microRNAs, which are single-stranded non-coding RNA molecules that alter gene expression by inhibiting target messenger RNA, are also being studied as an avenue to improve Treg function and stability [69–73].

To improve clinical outcomes, islet antigen-specific Tregs, which are in very low frequencies in peripheral blood, may need to be selectively expanded prior to infusion. Another approach is to combine these Treg expanding therapies with agents that modulate effector T cell function, such as monoclonal antibodies targeting CD3 on T cells [15,74–77], CD2 on T cells [78,79], antithymocyte globulin [80,81], or potentially a small molecule inhibitor of effector T cells activated by the T1D-risk HLA-DQ8 molecule in T1D [82–84]. Ideally, the effector T cell response would be modulated or blocked first, which is followed by a Treg-inducing agent. Finally, it would be of interest to the field to combine low-dose IL-2 with an islet antigen or to expand autologous Tregs in the presence of an epitope that is capable of inducing a regulatory immune response (such as the proinsulin epitopes depicted in Figure 1).

Antigen-specific immunotherapies have been trialed to both prevent clinical T1D onset and to preserve endogenous insulin function in new-onset patients with mixed results. Preparations of insulin (intradermal, intranasal, and oral) have not been able to prevent diabetes onset in those at risk and those having islet autoantibodies [85–87]; however, higher doses of oral insulin may have effects in those genetically at risk for T1D prior to the development of autoantibodies [88,89]. A GAD-alum vaccine has been used in newly diagnosed patients, again with less than optimal results in terms of preserving residual beta cell function [90,91]. However, there is strong evidence to suggest that individuals having a specific T1D risk HLA haplotype, DR3/DQ2 without DR4/DQ8, benefit from therapy [92,93]. As such, a clinical trial enrolling patients with this specific HLA-DR-DQ genotype is being planned and represents a personalized medicine approach to antigen-specific immunotherapy in T1D.

Insulin- and GAD-based intervention trials have made use of whole proteins; however, others have used self-peptides as antigen-specific therapy for T1D. In newly diagnosed patients, a DR4-restricted proinsulin peptide was injected intradermally without adjuvant every two weeks over the course of several months [94]. Compared to placebo, the peptide injection stabilized C-peptide levels as well as exogenous insulin use. Furthermore, peptide-treated individuals showed an increase in both Foxp3 expression within the Treg subset and increased IL-10 production by proinsulin-stimulated CD4 T cells compared to placebo-

treated individuals. Additionally, a recent phase 1 clinical trial used multiple-peptide immunotherapy with three epitopes from proinsulin and three from IA-2 that are presented by HLA-DR4, which were safe and tolerable [95]. These results indicate that peptide-specific immunomodulatory therapies may be able to induce both protective immunologic and metabolic responses even after the onset of clinical T1D.




Figure 1. Proinsulin epitopes that induce a regulatory immune response in type 1 diabetes. Displayed is the amino acid sequence of human proinsulin and the locations of peptides recognized by regulatory T cells with accompanying citations. Blue corresponds to amino acids within the B chain, black corresponds to amino acids within the C-peptide, and red corresponds to amino acids within the A chain of proinsulin. Epitopes include B:9-23 [40,42,43,49], B:11-30 [48], B:20-C4 [49], C:13-32 [41], C:19-A3 [41,49,51,94,95], C:22-A5 [41], A:1-15 [49], and overlapping peptides from insulin B chain, C-peptide, and insulin A chain [53].

8. Challenges and Gaps in the Field

Much evidence exists to suggest an imbalance of pathogenic versus Treg responses that leads to T1D. Studies evaluating effector and regulatory T cell responses to islet antigens have predominantly been performed using peripheral blood samples. Important questions remain, including whether the imbalance exists in different tissue compartments such as the pancreatic islets, exocrine pancreas, and pancreatic lymph nodes of patients. Studying tissue samples from organ donors at risk, with multiple islet autoantibodies but no overt clinical disease and with newly diagnosed T1D, will allow for important insights into these questions. Consortia such as the network for Pancreatic Organ Donors (nPOD) and the Human Pancreas Analysis Program (HPAP) are instrumental in identifying, collecting, and studying these rare tissue samples [96,97]. The advent of next-generation sequencing technologies, including those at the single-cell level (e.g., RNA sequencing, T cell receptor sequencing, and DNA methylation), provides an avenue to obtain large amounts of data on the molecular phenotype of cells within the target tissues of T1D.

Additional questions include: When in the disease process does an imbalance of effector to regulatory responses occur? Does a defect or imbalance in Tregs lead to a loss of tolerance or drive the disease toward clinical presentation after the development of islet autoimmunity, as indicated by the presence of islet autoantibodies? Longitudinal studies that follow children at-risk for T1D from birth, such as The Environmental Determinants of Diabetes in the Young (TEDDY) [98], will greatly aid in filling these gaps in the field.

Answering these questions will provide important insights into the pathogenesis of T1D and likely other organ-specific autoimmune diseases.

There is the striking finding that specific MHC class II molecules, DQ6 (DQB1*06:02) and DR15, provide dominant protection from T1D development. We propose the hypothesis that DQ6 and DR15 are capable of presenting self-peptides, including those from proinsulin and other islet-associated proteins that activate Tregs. Thus, a tolerogenic environment is induced when these peptides are encountered and presented in the periphery (Figure 2), whereas T1D risk MHC class II molecules, DQ8 and DR4, present similar peptides to effector T cells with those cells trafficking to the islets and promoting the eventual destruction of pancreatic beta cells. Evaluating this hypothesis will aid in understanding the mechanisms by which islet antigen Tregs restricted to diabetes-resistant MHC class II molecules provide protection, which will help design therapies to mimic these protective mechanisms to treat the underlying autoimmunity in T1D.




Figure 2. Potential mechanisms for protection from type 1 diabetes development by antigen-specific regulatory T cells. Depicted is a CD4⁺ regulatory T cell (Treg) recognizing an insulin or islet peptide in the context of diabetes-protective HLA-DQ6 or DR15. This interaction leads to the production of anti-inflammatory cytokines (e.g., IL-10 and TGF-β), and the activation of these antigen-specific Tregs can protect from beta cell destruction by four potential mechanisms. (1) CD4⁺ effector T cells recognize islet antigens presented by diabetes-risk conferring HLA-DQ8 or DR4 on antigen-presenting cells (APCs) and then migrate to the pancreas where they induce pancreatic beta cell destruction. Antigen-specific Tregs can suppress CD4⁺ effector T cells and prevent the trafficking of these cells to the pancreas via the release of anti-inflammatory cytokines. (2) CD8⁺ T effector cells in the pancreatic islets recognize islet antigens presented by HLA-A2 on pancreatic β cells, leading to the destruction of the β cells. Tregs can suppress CD8⁺ effector T cells and prevent β cell destruction via the release of anti-inflammatory cytokines. (3) Tregs can target APCs via granzyme-mediated killing in an antigen-independent manner or (4) potentially in an antigen-dependent manner when the cognate self-peptide is presented to the Treg T cell receptor (TCR).

9. Conclusions

Regulatory T cells specific to self-antigens from pancreatic insulin-producing beta-cells are present in both individuals with and without T1D. Interestingly, diabetes-resistant MHC class II molecules can also present islet antigens to Tregs, which may provide a mechanism to protect against disease development. Understanding how antigen-specific Tregs provide protection from T1D and other autoimmune diseases will aid in the development of therapies that mimic these protective mechanisms. Utilizing antigen-specific Tregs themselves or the antigens that stimulate them provide exciting avenues to induce tolerance in an organ-specific autoimmune disease such as T1D.

Author Contributions: A.M.M. and A.W.M. wrote and edited the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by NIH Grants (DK108868, DK110845, DK032083, DK099317, DK032493, DK116073), the Juvenile Diabetes Research Foundation (3-PDF-2020-943-A-N), the Leona M. & Harry B. Helmsley Charitable Trust (2103-05093), and the Colorado Clinical and Translational Science Institute (TR002535).

Conflicts of Interest: The authors declare no conflict of interest.

References

- Atkinson, M.A.; Eisenbarth, G.S.; Michels, A.W. Type 1 diabetes. *Lancet* **2014**, *383*, 69–82. [[CrossRef](#)]
- Bluestone, J.A.; Herold, K.; Eisenbarth, G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. *Nature* **2010**, *464*, 1293–1300. [[CrossRef](#)] [[PubMed](#)]
- Pugliese, A. Autoreactive T cells in type 1 diabetes. *J. Clin. Investig.* **2017**, *127*, 2881–2891. [[CrossRef](#)] [[PubMed](#)]
- Michels, A.W.; Redondo, M.J.; Atkinson, M.A. The pathogenesis, natural history, and treatment of type 1 diabetes: Time (thankfully) does not stand still. *Lancet Diabetes Endocrinol.* **2022**, *10*, 90–92. [[CrossRef](#)]
- Coppieters, K.T.; Dotta, F.; Amirian, N.; Campbell, P.D.; Kay, T.W.H.; Atkinson, M.A.; Roep, B.O.; von Herrath, M.G. Demonstration of islet-autoreactive CD8 T cells in insulinitic lesions from recent onset and long-term type 1 diabetes patients. *J. Exp. Med.* **2012**, *209*, 51–60. [[CrossRef](#)]
- Gepts, W. Pathologic anatomy of the pancreas in juvenile diabetes mellitus. *Diabetes* **1965**, *14*, 619–633. [[CrossRef](#)]
- Campbell-Thompson, M.; Fu, A.; Kaddis, J.S.; Wasserfall, C.; Schatz, D.A.; Pugliese, A.; Atkinson, M.A. Insulinitis and β -Cell Mass in the Natural History of Type 1 Diabetes. *Diabetes* **2016**, *65*, 719–731. [[CrossRef](#)]
- Arif, S.; Leete, P.; Nguyen, V.; Marks, K.; Nor, N.M.; Estorninho, M.; Kronenberg-Versteeg, D.; Bingley, P.J.; Todd, J.A.; Guy, C.; et al. Blood and islet phenotypes indicate immunological heterogeneity in type 1 diabetes. *Diabetes* **2014**, *63*, 3835–3845. [[CrossRef](#)]
- Leete, P.; Willcox, A.; Krogvold, L.; Dahl-Jørgensen, K.; Foulis, A.K.; Richardson, S.J.; Morgan, N.G. Differential Insulinitic Profiles Determine the Extent of β -Cell Destruction and the Age at Onset of Type 1 Diabetes. *Diabetes* **2016**, *65*, 1362–1369. [[CrossRef](#)]
- Hinman, R.M.; Cambier, J.C. Role of B lymphocytes in the pathogenesis of type 1 diabetes. *Curr. Diab. Rep.* **2014**, *14*, 543. [[CrossRef](#)]
- Mayer-Davis, E.J.; Lawrence, J.M.; Dabelea, D.; Divers, J.; Isom, S.; Dolan, L.; Imperatore, G.; Linder, B.; Marcovina, S.; Pettitt, D.J.; et al. Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002–2012. *N. Engl. J. Med.* **2017**, *376*, 1419–1429. [[CrossRef](#)] [[PubMed](#)]
- Insel, R.A.; Dunne, J.L.; Atkinson, M.A.; Chiang, J.L.; Dabelea, D.; Gottlieb, P.A.; Greenbaum, C.J.; Herold, K.C.; Krischer, J.P.; Lernmark, Å.; et al. Staging presymptomatic type 1 diabetes: A scientific statement of JDRE, the Endocrine Society, and the American Diabetes Association. *Diabetes Care* **2015**, *38*, 1964–1974. [[CrossRef](#)] [[PubMed](#)]
- Ziegler, A.G.; Rewers, M.; Simell, O.; Simell, T.; Lempainen, J.; Steck, A.; Winkler, C.; Ilonen, J.; Veijola, R.; Knip, M.; et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. *JAMA* **2013**, *309*, 2473–2479. [[CrossRef](#)]
- Simmons, K.M.; Michels, A.W. Type 1 diabetes: A predictable disease. *World J. Diabetes* **2015**, *6*, 380–390. [[CrossRef](#)]
- Herold, K.C.; Bundy, B.N.; Long, S.A.; Bluestone, J.A.; DiMeglio, L.A.; Dufort, M.J.; Gitelman, S.E.; Gottlieb, P.A.; Krischer, J.P.; Linsley, P.S.; et al. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. *N. Engl. J. Med.* **2019**, *381*, 603–613. [[CrossRef](#)]
- Tisch, R.; McDevitt, H. Insulin-dependent diabetes mellitus. *Cell* **1996**, *85*, 291–297. [[CrossRef](#)]
- Wicker, L.S.; Miller, B.J.; Fischer, P.A.; Pressey, A.; Peterson, L.B. Genetic control of diabetes and insulinitis in the nonobese diabetic mouse. Pedigree analysis of a diabetic H-2nod/b heterozygote. *J. Immunol.* **1989**, *142*, 781–784.
- Wicker, L.S.; Appel, M.C.; Dotta, F.; Pressey, A.; Miller, B.J.; DeLarato, N.H.; Fischer, P.A.; Boltz, R.C.; Peterson, L.B. Autoimmune syndromes in major histocompatibility complex (MHC) congenic strains of nonobese diabetic (NOD) mice. The NOD MHC is dominant for insulinitis and cyclophosphamide-induced diabetes. *J. Exp. Med.* **1992**, *176*, 67–77. [[CrossRef](#)] [[PubMed](#)]

19. Schmidt, D.; Verdaguer, J.; Averill, N.; Santamaria, P. A mechanism for the major histocompatibility complex-linked resistance to autoimmunity. *J. Exp. Med.* **1997**, *186*, 1059–1075. [[CrossRef](#)] [[PubMed](#)]
20. Lühder, F.; Katz, J.; Benoist, C.; Mathis, D. Major histocompatibility complex class II molecules can protect from diabetes by positively selecting T cells with additional specificities. *J. Exp. Med.* **1998**, *187*, 379–387. [[CrossRef](#)]
21. Tsai, S.; Serra, P.; Clemente-Casares, X.; Yamanouchi, J.; Thiessen, S.; Slattery, R.M.; Elliott, J.F.; Santamaria, P. Antidiabetogenic MHC class II promotes the differentiation of MHC-promiscuous autoreactive T cells into FOXP3⁺ regulatory T cells. *Proc. Natl. Acad. Sci. USA* **2013**, *110*, 3471–3476. [[CrossRef](#)] [[PubMed](#)]
22. Barrett, J.C.; Clayton, D.G.; Concannon, P.; Akolkar, B.; Cooper, J.D.; Erlich, H.A.; Julier, C.; Morahan, G.; Nerup, J.; Nierras, C.; et al. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. *Nat. Genet.* **2009**, *41*, 703–707. [[CrossRef](#)] [[PubMed](#)]
23. Hu, X.; Deutsch, A.J.; Lenz, T.L.; Onengut-Gumuscu, S.; Han, B.; Chen, W.M.; Howson, J.M.M.; Todd, J.A.; De Bakker, P.I.W.; Rich, S.S.; et al. Additive and interaction effects at three amino acid positions in HLA-DQ and HLA-DR molecules drive type 1 diabetes risk. *Nat. Genet.* **2015**, *47*, 898–905. [[CrossRef](#)]
24. Robertson, C.C.; Inshaw, J.R.J.; Onengut-Gumuscu, S.; Chen, W.-M.; Santa Cruz, D.F.; Yang, H.; Cutler, A.J.; Crouch, D.J.M.; Farber, E.; Bridges, S.L.; et al. Fine-mapping, trans-ancestral and genomic analyses identify causal variants, cells, genes and drug targets for type 1 diabetes. *Nat. Genet.* **2021**, *53*, 962–971. [[CrossRef](#)]
25. Dendrou, C.A.; Petersen, J.; Rossjohn, J.; Fugger, L. HLA variation and disease. *Nat. Rev. Immunol.* **2018**, *18*, 325–339. [[CrossRef](#)]
26. Erlich, H.; Valdes, A.M.; Noble, J.; Carlson, J.A.; Varney, M.; Concannon, P.; Mychaleckyj, J.C.; Todd, J.A.; Bonella, P.; Fear, A.L.; et al. HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: Analysis of the type 1 diabetes genetics consortium families. *Diabetes* **2008**, *57*, 1084–1092. [[CrossRef](#)]
27. Pugliese, A.; Boulware, D.; Yu, L.; Babu, S.; Steck, A.K.; Becker, D.; Rodriguez, H.; Di Meglio, L.; Evans-Molina, C.; Harrison, L.C.; et al. HLA-DRB1*15:01-DQA1*01:02-DQB1*06:02 haplotype protects autoantibody-positive relatives from type 1 diabetes throughout the stages of disease progression. *Diabetes* **2016**, *65*, 1109–1119. [[CrossRef](#)] [[PubMed](#)]
28. Simmons, K.M.; Mitchell, A.M.; Alkanani, A.A.; McDaniel, K.A.; Baschal, E.E.; Armstrong, T.; Pyle, L.; Yu, L.; Michels, A.W. Failed Genetic Protection: Type 1 Diabetes in the Presence of HLA-DQB1*06:02. *Diabetes* **2020**, *69*, 1763–1769. [[CrossRef](#)]
29. Nakayama, M.; Simmons, K.M.; Michels, A.W. Molecular Interactions Governing Autoantigen Presentation in Type 1 Diabetes. *Curr. Diab. Rep.* **2015**, *15*, 113. [[CrossRef](#)]
30. Grazia Roncarolo, M.; Gregori, S.; Battaglia, M.; Bacchetta, R.; Fleischhauer, K.; Levings, M.K. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. *Immunol. Rev.* **2006**, *212*, 28–50. [[CrossRef](#)]
31. Groux, H.; O’Garra, A.; Bigler, M.; Rouleau, M.; Antonenko, S.; de Vries, J.E.; Roncarolo, M.G. A CD4⁺ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. *Nature* **1997**, *389*, 737–742. [[CrossRef](#)] [[PubMed](#)]
32. Grossman, W.J.; Verbsky, J.W.; Tollefsen, B.L.; Kemper, C.; Atkinson, J.P.; Ley, T.J. Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. *Blood* **2004**, *104*, 2840–2848. [[CrossRef](#)] [[PubMed](#)]
33. Solé, P.; Santamaria, P. Re-Programming Autoreactive T Cells Into T-Regulatory Type 1 Cells for the Treatment of Autoimmunity. *Front. Immunol.* **2021**, *12*, 684240. [[CrossRef](#)] [[PubMed](#)]
34. Lindley, S.; Dayan, C.M.; Bishop, A.; Roep, B.O.; Peakman, M.; Tree, T.I.M. Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. *Diabetes* **2005**, *54*, 92–99. [[CrossRef](#)]
35. Brusko, T.M.; Wasserfall, C.H.; Clare-Salzler, M.J.; Schatz, D.A.; Atkinson, M.A. Functional defects and the influence of age on the frequency of CD4⁺ CD25⁺ T-cells in type 1 diabetes. *Diabetes* **2005**, *54*, 1407–1414. [[CrossRef](#)] [[PubMed](#)]
36. Haseda, F.; Imagawa, A.; Murase-Mishiba, Y.; Terasaki, J.; Hanafusa, T. CD4⁺ CD45RA⁻ FoxP3^{high} activated regulatory T cells are functionally impaired and related to residual insulin-secreting capacity in patients with type 1 diabetes. *Clin. Exp. Immunol.* **2013**, *173*, 207–216. [[CrossRef](#)]
37. Hull, C.M.; Peakman, M.; Tree, T.I.M. Regulatory T cell dysfunction in type 1 diabetes: what’s broken and how can we fix it? *Diabetologia* **2017**, *60*, 1839–1850. [[CrossRef](#)]
38. Danke, N.A.; Koelle, D.M.; Yee, C.; Beheray, S.; Kwok, W.W. Autoreactive T Cells in Healthy Individuals. *J. Immunol.* **2004**, *172*, 5967–5972. [[CrossRef](#)]
39. Yang, J.; Danke, N.A.; Berger, D.; Reichstetter, S.; Reijonen, H.; Greenbaum, C.; Pihoker, C.; James, E.A.; Kwok, W.W. Islet-Specific Glucose-6-Phosphatase Catalytic Subunit-Related Protein-Reactive CD4⁺ T Cells in Human Subjects. *J. Immunol.* **2006**, *176*, 2781–2789. [[CrossRef](#)]
40. Nakayama, M.; McDaniel, K.; Fitzgerald-Miller, L.; Kiekhäfer, C.; Snell-Bergeon, J.K.; Davidson, H.W.; Rewers, M.; Yu, L.; Gottlieb, P.; Kappler, J.W.; et al. Regulatory vs. inflammatory cytokine T-cell responses to mutated insulin peptides in healthy and type 1 diabetic subjects. *Proc. Natl. Acad. Sci. USA* **2015**, *112*, 4429–4434. [[CrossRef](#)]
41. Arif, S.; Tree, T.I.; Astill, T.P.; Tremble, J.M.; Bishop, A.J.; Dayan, C.M.; Roep, B.O.; Peakman, M. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. *J. Clin. Investig.* **2004**, *113*, 451–463. [[CrossRef](#)] [[PubMed](#)]
42. Arif, S.; Pujol-Autonell, I.; Kamra, Y.; Williams, E.; Yusuf, N.; Domingo-Vila, C.; Shahrabi, Y.; Pollock, E.; Khatri, L.; Peakman, M.; et al. Mapping T Cell Responses to Native and Neo-Islet Antigen Epitopes in at Risk and Type 1 Diabetes Subjects. *Front. Immunol.* **2021**, *12*, 675746. [[CrossRef](#)] [[PubMed](#)]

43. Mitchell, A.M.; Alkanani, A.A.; McDaniel, K.A.; Pyle, L.; Waugh, K.; Steck, A.K.; Nakayama, M.; Yu, L.; Gottlieb, P.A.; Rewers, M.J.; et al. T-cell responses to hybrid insulin peptides prior to type 1 diabetes development. *Proc. Natl. Acad. Sci. USA* **2021**, *118*, e2019129118. [[CrossRef](#)]
44. Delong, T.; Wiles, T.A.; Baker, R.L.; Bradley, B.; Barbour, G.; Reisdorph, R.; Armstrong, M.; Powell, R.L.; Reisdorph, N.; Kumar, N.; et al. Pathogenic CD4 T cells in type 1 diabetes recognize epitopes formed by peptide fusion. *Science* **2016**, *351*, 711–714. [[CrossRef](#)]
45. Baker, R.L.; Rihanek, M.; Hohenstein, A.C.; Nakayama, M.; Michels, A.; Gottlieb, P.A.; Haskins, K.; Delong, T. Hybrid Insulin Peptides Are Autoantigens in Type 1 Diabetes. *Diabetes* **2019**, *68*, 1830–1840. [[CrossRef](#)] [[PubMed](#)]
46. Arribas-Layton, D.; Guyer, P.; Delong, T.; Dang, M.; Chow, I.-T.; Speake, C.; Greenbaum, C.J.; Kwok, W.W.; Baker, R.L.; Haskins, K.; et al. Hybrid Insulin Peptides are Recognized by Human T Cells in the Context of DRB1*04:01. *Diabetes* **2020**. [[CrossRef](#)] [[PubMed](#)]
47. Wiles, T.A.; Hohenstein, A.; Landry, L.G.; Dang, M.; Powell, R.; Guyer, P.; James, E.A.; Nakayama, M.; Haskins, K.; Delong, T.; et al. Characterization of Human CD4 T Cells Specific for a C-Peptide/C-Peptide Hybrid Insulin Peptide. *Front. Immunol.* **2021**, *12*, 668680. [[CrossRef](#)] [[PubMed](#)]
48. Tree, T.I.M.; Lawson, J.; Edwards, H.; Skowera, A.; Arif, S.; Roep, B.O.; Peakman, M. Naturally Arising Human CD4 T-Cells That Recognize Islet Autoantigens and Secrete Interleukin-10 Regulate Proinflammatory T-Cell Responses via Linked Suppression. *Diabetes* **2010**, *59*, 1451–1460. [[CrossRef](#)]
49. Chujo, D.; Nguyen, T.-S.; Foucat, E.; Blankenship, D.; Banchereau, J.; Nepom, G.T.; Chaussabel, D.; Ueno, H. Adult-onset type 1 diabetes patients display decreased IGRP-specific Tr1 cells in blood. *Clin. Immunol.* **2015**, *161*, 270–277. [[CrossRef](#)]
50. Spence, A.; Purtha, W.; Tam, J.; Dong, S.; Kim, Y.; Ju, C.; Sterling, T.; Nakayama, M.; Robinson, W.H.; Bluestone, J.A.; et al. Revealing the specificity of regulatory T cells in murine autoimmune diabetes. *Proc. Natl. Acad. Sci. USA* **2018**, *115*, 5265–5270. [[CrossRef](#)]
51. Beringer, D.X.; Kleijwegt, F.S.; Wiede, F.; van der Slik, A.R.; Loh, K.L.; Petersen, J.; Dudek, N.L.; Duinkerken, G.; Laban, S.; Joosten, A.; et al. T cell receptor reversed polarity recognition of a self-antigen major histocompatibility complex. *Nat. Immunol.* **2015**, *16*, 1153–1161. [[CrossRef](#)] [[PubMed](#)]
52. Gras, S.; Chadderton, J.; Del Campo, C.M.; Farenc, C.; Wiede, F.; Josephs, T.M.; Sng, X.Y.X.; Mirams, M.; Watson, K.A.; Tiganis, T.; et al. Reversed T Cell Receptor Docking on a Major Histocompatibility Class I Complex Limits Involvement in the Immune Response. *Immunity* **2016**, *45*, 749–760. [[CrossRef](#)] [[PubMed](#)]
53. Wen, X.; Yang, J.; James, E.; Chow, I.T.; Reijonen, H.; Kwok, W.W. Increased islet antigen-specific regulatory and effector CD4+ T cells in healthy individuals with the type 1 diabetes-protective haplotype. *Sci. Immunol.* **2020**, *5*, eaax8767. [[CrossRef](#)]
54. Ooi, J.D.; Petersen, J.; Tan, Y.H.; Huynh, M.; Willett, Z.J.; Ramarathinam, S.H.; Eggenhuizen, P.J.; Loh, K.L.; Watson, K.A.; Gan, P.Y.; et al. Dominant protection from HLA-linked autoimmunity by antigen-specific regulatory T cells. *Nature* **2017**, *545*, 243–247. [[CrossRef](#)] [[PubMed](#)]
55. Ye, C.; Brand, D.; Zheng, S.G. Targeting IL-2: An unexpected effect in treating immunological diseases. *Signal Transduct. Target. Ther.* **2018**, *3*, 2. [[CrossRef](#)] [[PubMed](#)]
56. Ballesteros-Tato, A. Beyond regulatory T cells: The potential role for IL-2 to deplete T-follicular helper cells and treat autoimmune diseases. *Immunotherapy* **2014**, *6*, 1207–1220. [[CrossRef](#)] [[PubMed](#)]
57. Long, S.A.; Rieck, M.; Sanda, S.; Bollyky, J.B.; Samuels, P.L.; Goland, R.; Ahmann, A.; Rabinovitch, A.; Aggarwal, S.; Phippard, D.; et al. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β -cell function. *Diabetes* **2012**, *61*, 2340–2348. [[CrossRef](#)]
58. Rosenzweig, M.; Churlaud, G.; Mallone, R.; Six, A.; Dérian, N.; Chaara, W.; Lorenzon, R.; Long, S.A.; Buckner, J.H.; Afonso, G.; et al. Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients. *J. Autoimmun.* **2015**, *58*, 48–58. [[CrossRef](#)]
59. Yu, A.; Snowwhite, I.; Vendrame, F.; Rosenzweig, M.; Klatzmann, D.; Pugliese, A.; Malek, T.R. Selective IL-2 responsiveness of regulatory T cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes. *Diabetes* **2015**, *64*, 2172–2183. [[CrossRef](#)]
60. Waldron-Lynch, F.; Kareclas, P.; Irons, K.; Walker, N.M.; Mander, A.; Wicker, L.S.; Todd, J.A.; Bond, S. Rationale and study design of the Adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D): A non-randomised, open label, adaptive dose finding trial. *BMJ Open* **2014**, *4*, e005559. [[CrossRef](#)]
61. Todd, J.A.; Evangelou, M.; Cutler, A.J.; Pekalski, M.L.; Walker, N.M.; Stevens, H.E.; Porter, L.; Smyth, D.J.; Rainbow, D.B.; Ferreira, R.C.; et al. Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial. *PLoS Med.* **2016**, *13*, e1002139. [[CrossRef](#)] [[PubMed](#)]
62. Seelig, E.; Howlett, J.; Porter, L.; Truman, L.; Heywood, J.; Kennet, J.; Arbon, E.L.; Anselmiova, K.; Walker, N.M.; Atkar, R.; et al. The DILfrequency study is an adaptive trial to identify optimal IL-2 dosing in patients with type 1 diabetes. *JCI Insight* **2018**, *3*, e99306. [[CrossRef](#)] [[PubMed](#)]
63. Hartemann, A.; Bensimon, G.; Payan, C.A.; Jacqueminet, S.; Bourron, O.; Nicolas, N.; Fonfrede, M.; Rosenzweig, M.; Bernard, C.; Klatzmann, D. Low-dose interleukin 2 in patients with type 1 diabetes: A phase 1/2 randomised, double-blind, placebo-controlled trial. *Lancet Diabetes Endocrinol.* **2013**, *1*, 295–305. [[CrossRef](#)]

64. Rosenzweig, M.; Salet, R.; Lorenzon, R.; Tchitchek, N.; Roux, A.; Bernard, C.; Carel, J.-C.; Storey, C.; Polak, M.; Beltrand, J.; et al. Low-dose IL-2 in children with recently diagnosed type 1 diabetes: A Phase I/II randomised, double-blind, placebo-controlled, dose-finding study. *Diabetologia* **2020**, *63*, 1808–1821. [[CrossRef](#)] [[PubMed](#)]
65. Bluestone, J.A.; Buckner, J.H.; Fitch, M.; Gitelman, S.E.; Gupta, S.; Hellerstein, M.K.; Herold, K.C.; Lares, A.; Lee, M.R.; Li, K.; et al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. *Sci. Transl. Med.* **2015**, *7*, 315ra189. [[CrossRef](#)]
66. Putnam, A.L.; Brusko, T.M.; Lee, M.R.; Liu, W.; Szot, G.L.; Ghosh, T.; Atkinson, M.A.; Bluestone, J.A. Expansion of human regulatory T-cells from patients with type 1 diabetes. *Diabetes* **2009**, *58*, 652–662. [[CrossRef](#)]
67. Dong, S.; Hiam-Galvez, K.J.; Mowery, C.T.; Herold, K.C.; Gitelman, S.E.; Esensten, J.H.; Liu, W.; Lares, A.P.; Leinbach, A.S.; Lee, M.; et al. The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes. *JCI Insight* **2021**, *6*, e147474. [[CrossRef](#)]
68. Sockolovsky, J.T.; Trotta, E.; Parisi, G.; Picton, L.; Su, L.L.; Le, A.C.; Chhabra, A.; Silveria, S.L.; George, B.M.; King, I.C.; et al. Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes. *Science* **2018**, *359*, 1037–1042. [[CrossRef](#)]
69. Serr, I.; Scherm, M.G.; Zahm, A.M.; Schug, J.; Flynn, V.K.; Hippich, M.; Kälin, S.; Becker, M.; Achenbach, P.; Nikolaev, A.; et al. A miRNA181a/NFAT5 axis links impaired T cell tolerance induction with autoimmune type 1 diabetes. *Sci. Transl. Med.* **2018**, *10*, eaag1782. [[CrossRef](#)]
70. Scherm, M.G.; Serr, I.; Zahm, A.M.; Schug, J.; Bellusci, S.; Manfredini, R.; Salb, V.K.; Gerlach, K.; Weigmann, B.; Ziegler, A.-G.; et al. miRNA142-3p targets Tet2 and impairs Treg differentiation and stability in models of type 1 diabetes. *Nat. Commun.* **2019**, *10*, 5697. [[CrossRef](#)]
71. Serr, I.; Fürst, R.W.; Ott, V.B.; Scherm, M.G.; Nikolaev, A.; Gökmen, F.; Kälin, S.; Zillmer, S.; Bunk, M.; Weigmann, B.; et al. miRNA92a targets KLF2 and the phosphatase PTEN signaling to promote human T follicular helper precursors in T1D islet autoimmunity. *Proc. Natl. Acad. Sci. USA* **2016**, *113*, E6659–E6668. [[CrossRef](#)] [[PubMed](#)]
72. Garavelli, S.; Bruzzaniti, S.; Tagliabue, E.; Prattichizzo, F.; Di Silvestre, D.; Perna, F.; La Sala, L.; Ceriello, A.; Mozzillo, E.; Fattorusso, V.; et al. Blood Co-Circulating Extracellular microRNAs and Immune Cell Subsets Associate with Type 1 Diabetes Severity. *Int. J. Mol. Sci.* **2020**, *21*, 477. [[CrossRef](#)] [[PubMed](#)]
73. Sebastiani, G.; Ventriglia, G.; Stabilini, A.; Socci, C.; Morsiani, C.; Laurenzi, A.; Nigi, L.; Formichi, C.; Mfarrej, B.; Petrelli, A.; et al. Regulatory T-cells from pancreatic lymphnodes of patients with type-1 diabetes express increased levels of microRNA miR-125a-5p that limits CCR2 expression. *Sci. Rep.* **2017**, *7*, 6897. [[CrossRef](#)] [[PubMed](#)]
74. Herold, K.C.; Hagopian, W.; Auger, J.A.; Poumian-Ruiz, E.; Taylor, L.; Donaldson, D.; Gitelman, S.E.; Harlan, D.M.; Xu, D.; Zivin, R.A.; et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. *N. Engl. J. Med.* **2002**, *346*, 1692–1698. [[CrossRef](#)]
75. Keymeulen, B.; Vandemeulebroucke, E.; Ziegler, A.G.; Mathieu, C.; Kaufman, L.; Hale, G.; Gorus, F.; Goldman, M.; Walter, M.; Candon, S.; et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. *N. Engl. J. Med.* **2005**, *352*, 2598–2608. [[CrossRef](#)]
76. Sherry, N.; Hagopian, W.; Ludvigsson, J.; Jain, S.M.; Wahlen, J.; Ferry, R.J.; Bode, B.; Aronoff, S.; Holland, C.; Carlin, D.; et al. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. *Lancet* **2011**, *378*, 487–497. [[CrossRef](#)]
77. Sims, E.K.; Bundy, B.N.; Stier, K.; Serti, E.; Lim, N.; Long, S.A.; Geyer, S.M.; Moran, A.; Greenbaum, C.J.; Evans-Molina, C.; et al. Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. *Sci. Transl. Med.* **2021**, *13*, eabc8980. [[CrossRef](#)]
78. Rigby, M.R.; DiMeglio, L.A.; Rendell, M.S.; Felner, E.I.; Dostou, J.M.; Gitelman, S.E.; Patel, C.M.; Griffin, K.J.; Tsalikian, E.; Gottlieb, P.A.; et al. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (TIDAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. *Lancet Diabetes Endocrinol.* **2013**, *1*, 284–294. [[CrossRef](#)]
79. Rigby, M.R.; Harris, K.M.; Pinckney, A.; DiMeglio, L.A.; Rendell, M.S.; Felner, E.I.; Dostou, J.M.; Gitelman, S.E.; Griffin, K.J.; Tsalikian, E.; et al. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. *J. Clin. Investig.* **2015**, *125*, 3285–3296. [[CrossRef](#)]
80. Haller, M.J.; Gitelman, S.E.; Gottlieb, P.A.; Michels, A.W.; Rosenthal, S.M.; Shuster, J.J.; Zou, B.; Brusko, T.M.; Hulme, M.A.; Wasserfall, C.H.; et al. Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes. *J. Clin. Investig.* **2015**, *125*, 448–455. [[CrossRef](#)]
81. Haller, M.J.; Schatz, D.A.; Skyler, J.S.; Krischer, J.P.; Bundy, B.N.; Miller, J.L.; Atkinson, M.A.; Becker, D.J.; Baidal, D.; DiMeglio, L.A.; et al. Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β -Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes. *Diabetes Care* **2018**, *41*, 1917–1925. [[CrossRef](#)] [[PubMed](#)]
82. Michels, A.W.; Ostrov, D.A.; Zhang, L.; Nakayama, M.; Fuse, M.; McDaniel, K.; Roep, B.O.; Gottlieb, P.A.; Atkinson, M.A.; Eisenbarth, G.S. Structure-based selection of small molecules to alter allele-specific MHC class II antigen presentation. *J. Immunol.* **2011**, *187*, 5921–5930. [[CrossRef](#)] [[PubMed](#)]
83. Ostrov, D.A.; Alkanani, A.; McDaniel, K.A.; Case, S.; Baschal, E.E.; Pyle, L.; Ellis, S.; Pöllinger, B.; Seidl, K.J.; Shah, V.N.; et al. Methyl dopa blocks MHC class II binding to disease-specific antigens in autoimmune diabetes. *J. Clin. Investig.* **2018**, *128*, 1888–1902. [[CrossRef](#)] [[PubMed](#)]
84. Ostrov, D.A.; Gottlieb, P.A.; Michels, A.W. Rationally designed small molecules to prevent type 1 diabetes. *Curr. Opin. Endocrinol. Diabetes. Obes.* **2019**, *26*, 90–95. [[CrossRef](#)]

85. Diabetes Prevention Trial—Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. *N. Engl. J. Med.* **2002**, *346*, 1685–1691. [[CrossRef](#)]
86. Näntö-Salonen, K.; Kupila, A.; Simell, S.; Siljander, H.; Salonsaari, T.; Hekkala, A.; Korhonen, S.; Erkkola, R.; Sipilä, J.I.; Haavisto, L.; et al. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: A double-blind, randomised controlled trial. *Lancet* **2008**, *372*, 1746–1755. [[CrossRef](#)]
87. Writing Committee for the Type 1 Diabetes TrialNet Oral Insulin Study Group; Krischer, J.P.; Schatz, D.A.; Bundy, B.; Skyler, J.S.; Greenbaum, C.J. Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients With Type 1 Diabetes: A Randomized Clinical Trial. *JAMA* **2017**, *318*, 1891–1902. [[CrossRef](#)]
88. Bonifacio, E.; Ziegler, A.-G.; Klingensmith, G.; Schober, E.; Bingley, P.J.; Rottenkolber, M.; Theil, A.; Eugster, A.; Puff, R.; Peplow, C.; et al. Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: The Pre-POINT randomized clinical trial. *JAMA* **2015**, *313*, 1541–1549. [[CrossRef](#)]
89. Assfalg, R.; Knoop, J.; Hoffman, K.L.; Pfirrmann, M.; Zapardiel-Gonzalo, J.M.; Hofelich, A.; Eugster, A.; Weigelt, M.; Matzke, C.; Reinhardt, J.; et al. Oral insulin immunotherapy in children at risk for type 1 diabetes in a randomised controlled trial. *Diabetologia* **2021**, *64*, 1079–1092. [[CrossRef](#)]
90. Ludvigsson, J.; Faresjö, M.; Hjorth, M.; Axelsson, S.; Chéramy, M.; Pihl, M.; Vaarala, O.; Forsander, G.; Ivarsson, S.; Johansson, C.; et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. *N. Engl. J. Med.* **2008**, *359*, 1909–1920. [[CrossRef](#)]
91. Wherrett, D.K.; Bundy, B.; Becker, D.J.; DiMeglio, L.A.; Gitelman, S.E.; Goland, R.; Gottlieb, P.A.; Greenbaum, C.J.; Herold, K.C.; Marks, J.B.; et al. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: A randomised double-blind trial. *Lancet* **2011**, *378*, 319–327. [[CrossRef](#)]
92. Hannelius, U.; Beam, C.A.; Ludvigsson, J. Efficacy of GAD-alum immunotherapy associated with HLA-DR3-DQ2 in recently diagnosed type 1 diabetes. *Diabetologia* **2020**, *63*, 2177–2181. [[CrossRef](#)] [[PubMed](#)]
93. Ludvigsson, J.; Sumnik, Z.; Pelikanova, T.; Nattero Chavez, L.; Lundberg, E.; Rica, I.; Martínez-Brocca, M.A.; Ruiz de Adana, M.; Wahlberg, J.; Katsarou, A.; et al. Intralymphatic Glutamic Acid Decarboxylase With Vitamin D Supplementation in Recent-Onset Type 1 Diabetes: A Double-Blind, Randomized, Placebo-Controlled Phase IIb Trial. *Diabetes Care* **2021**, *44*, 1604–1612. [[CrossRef](#)] [[PubMed](#)]
94. Alhadj Ali, M.; Liu, Y.-F.; Arif, S.; Tatovic, D.; Shariff, H.; Gibson, V.B.; Yusuf, N.; Baptista, R.; Eichmann, M.; Petrov, N.; et al. Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes. *Sci. Transl. Med.* **2017**, *9*, eaaf7779. [[CrossRef](#)]
95. Liu, Y.-F.; Powrie, J.; Arif, S.; Yang, J.H.M.; Williams, E.; Khatri, L.; Joshi, M.; Lhuillier, L.; Fountoulakis, N.; Smith, E.; et al. Immune and Metabolic Effects of Antigen-Specific Immunotherapy Using Multiple β -Cell Peptides in Type 1 Diabetes. *Diabetes* **2022**. [[CrossRef](#)] [[PubMed](#)]
96. Campbell-Thompson, M.; Wasserfall, C.; Kaddis, J.; Albanese-O’Neill, A.; Staeva, T.; Nierras, C.; Moraski, J.; Rowe, P.; Gianani, R.; Eisenbarth, G.; et al. Network for Pancreatic Organ Donors with Diabetes (nPOD): Developing a tissue biobank for type 1 diabetes. *Diabetes. Metab. Res. Rev.* **2012**, *28*, 608–617. [[CrossRef](#)] [[PubMed](#)]
97. Kaestner, K.H.; Powers, A.C.; Naji, A.; HPAP Consortium; Atkinson, M.A. NIH Initiative to Improve Understanding of the Pancreas, Islet, and Autoimmunity in Type 1 Diabetes: The Human Pancreas Analysis Program (HPAP). *Diabetes* **2019**, *68*, 1394–1402. [[CrossRef](#)] [[PubMed](#)]
98. Hagopian, W.A.; Lernmark, A.; Rewers, M.J.; Simell, O.G.; She, J.-X.; Ziegler, A.G.; Krischer, J.P.; Akolkar, B. TEDDY—The Environmental Determinants of Diabetes in the Young: An observational clinical trial. *Ann. N. Y. Acad. Sci.* **2006**, *1079*, 320–326. [[CrossRef](#)] [[PubMed](#)]